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ABSTRACT
The detection of promoter region hyermethylation and transcriptional silencing has facilitated the identification of candidate renal cell carcinoma (RCC) tumour suppressor genes (TSGs). We have utilised a genome-wide strategy (methylated DNA Immunoprecipitation (MeDIP) and whole genome array analysis in combination with high-density expression array analysis) to identify genes that are frequently methylated and silenced in RCC. MeDIP analysis on 9 RCC tumours and 3 non-malignant normal kidney tissue samples was performed and an initial shortlist of 56 candidate genes that were methylated by array analysis were further investigated, 9 genes were confirmed to show frequent promoter region methylation in primary RCC tumour samples (KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%), CCDC8 (35%), FBN2 (34%), ATP5G2 (36%), PCDH8 (58%) and CORO6 (22%). RNAi knock-down for KLHL35, QPCT, SCUBE3, ZSCAN18, CCDC8 and FBN2 resulted in an anchorage independent growth advantage. Tumour methylation of SCUBE3 was associated with a significantly increased risk of cancer death or relapse (P=0.0046). The identification of candidate epigenetically inactivated RCC TSGs provides new insights into renal tumourigenesis.


INTRODUCTION
	Erroneous hypermethylation of CpG islands associated with gene promoters induces transcriptional silencing via multiple mechanisms involved in chromatin modification  (Li et al 2007). Since the identification of RB1 tumour suppressor gene (TSG) inactivation by promoter hypermethylation 17 years ago (Ohtani-Fujita et al 1993)	it has become increasingly apparent that tumour suppressor promoter methylation plays a significant role in the clonal evolution of cancer. For renal cell carcinoma, large-scale sequencing projects have revealed that with the exception of the VHL TSG, candidate TSGs are mutated in <10% of tumours (Dalgliesh et al 2010) whilst a much larger number of TSGs are frequently silenced by cancer-specific promoter methylation. Indeed, several important RCC TSGs are frequently inactivated by promoter hypermethylation but rarely mutated, these include; RASSF1A (Hogg et al 2002, Morris et al 2003, Morrissey et al 2001), SFRP1 (Dahl et al 2007, Morris et al 2010), DAPK1 (Christoph et al 2006, Morris et al 2003) and SPINT2 (Morris et al 2005). These observations, in combination with the frequent difficulty of distinguishing “driver” and “passenger” mutations in human cancers, suggest that strategies to identify genes targeted by de novo promoter methylation can provide an efficient approach to identify novel RCC TSGS.
	In the past decade the tools available to those wishing to identify epigenetically silenced genes in cancer have developed rapidly. Initially, significant progress was made by functional epigenomic approaches utilising gene expression microarrays to study changes in gene expression following global demethylation of cancer cell line genomes (Lodygin et al 2005, Sato et al 2003, Yamashita et al 2002). For RCC this approach resulted in the identification of ~14 candidate RCC TSGs (Ibanez de Caceres et al 2006, Morris et al 2005, Morris et al 2008, Morris et al 2010). However, the application of this strategy is limited as evidence by the observation that many of the genes that are upregulated in RCC cell lines do not show promoter methylation and that many genes that are methylated in cell lines are not methylated in primary tumours (Morris et al 2008, Morris et al 2010). The technique of Methylated DNA Immunoprecipitation (MeDIP) enables the isolation of the methylated DNA fraction form primary tumour DNA which can then be analysed by high-density whole genome microarray, so allowing the direct analysis of genomic methylation patterns in primary tumours. Previously, no whole genome methylation detection strategies have been applied to the analysis of methylation in RCC. We have utilised methylated-DNA Immunoprecipitation with comparative high-density whole genome microarray analysis to identify differentially methylated regions in primary tumour DNA directly. We have combined this data with expression array data from RCC-derived cell lines that have been globally de-methylated by treatment with 5-Aza-2’-deoxycytidine to increase the likelihood of identifying tumour-specific methylation that correlates to gene silencing. We have identified a number of genes that are frequently methylated in an RCC tumour-specific manner resulting in gene silencing. We have also identified a subset of these genes that have shown in vitro tumour suppressor activity. 






METHODS

Patients and samples
 DNA from up to 69 primary RCCs (approximately 80% clear cell, 20% non-clear cell) and matched adjacent macroscopically normal renal tissue and normal renal tissue from 6 patients undergoing non-cancer renal surgery (mean age 57 years, range from 23-79 years) were analysed. Nine tumour DNAs were used for MeDIP array analysis. Twenty tumour DNA samples were used to confirm initial array results and a further 40 were used to follow up positive candidate genes (total=69) Local research ethics committees approved the collection of samples and informed consent was obtained from each patient. This study was conducted according to the principles expressed in the Declaration of Helsinki. 
Cell lines, 5-Aza-2’-deoxycytidine treatment and microarray analysis. RCC cell lines KTCL26, RCC4, UMRC2, UMRC3, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54, 786-O, Caki-1, CAL54, RCC48, RCC1, RCC12, Caki-2, A498, ACHN and 769-P were routinely maintained in DMEM (Invitrogen, San Diego, CA) supplemented with 10% FCS at 37°C, 5% CO2. The demethylating agent 5-Aza-2’-deoxycytidine (Sigma) was freshly prepared in dd H2O and filter sterilized. Cell lines were plated in 75-cm2 flasks in DMEM supplemented with 10% FCS at differing densities, depending upon their doubling time, to ensure that both control and 5-Aza-2’-deoxycytidine treated lines reached approximately 75% confluency at the point of RNA extraction. Twenty-four hrs later, cells were treated with 5 μM 5-Aza-2’-deoxycytidine. The medium was changed 24 hrs after treatment and then changed again after 72hrs. RNA was prepared 5 days after treatment using RNABee (AMS Biotechnology). Total RNA from all 19 cell lines +/-5-Aza-2’-deoxycytidine was isolated using RNA-Bee reagent following manufacturer’s instructions (AMS Bio) followed by purification using RNeasy Mini-columns (Qiagen). cRNA probes from KTCL26, RCC4, UMRC2, UMRC3, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54, 786-O, Caki-1 cell lines were prepared using the Affymetrix protocol and hybridized to HG-U133 plus2 GeneChip oligonucleotide arrays (Affymetrix). Array hybridisation and data production was done by the CRUK Paterson Institute Microarray Service (http://bioinformatics.picr.man.ac.uk/mbcf/ (​http:​/​​/​bioinformatics.picr.man.ac.uk​/​mbcf​/​​)). cRNA probes for , CAL54, RCC48, RCC1, RCC12, Caki-2, A498, ACHN and 769-P lines were prepared using the Illumina method and hybridized to Human WG-6 geneChip arrays (Illumina).
MeDIP DNA preparation and analysis 

MeDIP was performed as per the suggested protocol of Nimblegen. RNA-free genomic DNA was extracted from RCC cell lines and tumours by standard methods. 6µg each DNA sample was digested overnight at 37oC with 24U MseI (supplemented with 100ng/µl BSA). The reactions were stopped by heating at 65oC for 20 minutes, and the success of the reactions was verified by running a small aliquot of the digested DNA on an agarose gel. DNA was quantified using a NanoDrop spectrophotometer, and 1.25 µg DNA was diluted in TE buffer to a final volume of 300µl. The DNA was denatured at 95oC for 10 minutes, and 60µl (250ng) was removed for use as control (input) DNA. 60µl 5xIP buffer (100mM Na Phosphate pH7.0, 5M Nacl, 10% Triton X-100) and 1 µg IP antibody (mouse monoclonal anti-5-methylcytidine, Eurogentec) were added to the remaining DNA, and the mixture was incubated overnight at 4oC with gentle rotation. 24µl Protein A agarose beads were pre-washed twice in PBS / 0.1% BSA, and resuspended in 24µl 1xIP buffer; this 50% slurry was added to the DNA/antibody mixture, and incubated for 2 hours at 4oC with gentle rotation. The beads were washed three times with 1xIP buffer, and resuspended in 250µl digestion buffer (1M Tris HCl pH 8.0, 0.5M EDTA, 10% SDS; filter sterilised). 7µl 10mg/ml proteinase K was added to the above mixture, and incubation was carried out overnight at 55oC. DNA was purified by phenol/chloroform extraction and ethanol precipitation (the latter with the addition of 20µg glycogen to facilitate visualisation of the DNA pellet). 10ng input DNA and 10ng IP DNA were subjected to Whole Genome Amplification with the WGA2 kit (Sigma), and purified using the Qiaquick PCR purification kit (Qiagen). 4µg input and IP DNA were sent to Nimblegen Laboratories, differentially labelled and applied to the HG18 RefSeq Human Promoter Array.

RT PCR conditions

PCR cycling conditions consisted of 5 min at 95°C followed by 30 cycles of 45 sec of denaturation at 95°C, 45 sec of annealing at 55-60°C and 45 sec of extension at 72°C. Semi-quantitative analysis of expression was done using LabWorks software (Ultraviolet products, California). (RT PCR primers and conditions upon request). 
Bisulfite Modification. 
0.5–1.0 μg of genomic DNA was denatured in 0.3 M NaOH for 15 min at 37°C, and then unmethylated cytosine residues were sulfonated by incubation in 3.12 M sodium bisulfite (pH 5.0; Sigma)/5 mM hydroquinone (Sigma) in a thermocycler (Hybaid) for 20 cycles of 30 s at 99°C and 15 min at 50°C. The sulfonated DNA was recovered using the Wizard DNA cleanup system (Promega) in accordance with the manufacturer’s instructions. The conversion reaction was completed by desulfonating in 0.3 M NaOH for 10 min at room temperature. The DNA was ethanol-precipitated and resuspended in water. 

Promoter Methylation Analysis
CpG islands were identified on the human genome browser and putative promoter regions were predicted by Promoter Inspector software (Genomatix). Primers used to amplify these regions from bisulphite modified DNA can be found in Supplementary Table 1. Promoter region methylation in cell lines was identified by direct sequencing of bisulphite PCR products as described previously (Morris et al 2005). Combined Bisulphite and Restriction analysis (CoBRA) was carried out by digesting bisulphite-PCR products with BstU1. Promoter methylation analysis of tumour DNA was done by cloning bisulphite-PCR products into pGEM (Promega) followed by sequencing of individual clones using primers to T7 or M13.
Anchorage Independent Growth Assay. 
RNAi “silencer select” oligos against KLHL35 (s49143), FBN2 (s5049), ATP5G2 (s1781), SOX14 (s15948), CORO6 (s39713), CCDC8 (s228331), PCDH8 (s10114), SCUBE3 (s48237), ZSCAN18 (s35299) and QPCT (s24500) or “Silencer select” control oligo no.1 (Ambion) were transfected into HEK-293 cells using Interferin reagent (Polyplus) following the manufacture’s instructions. After 24h incubation cells were seeded into 2ml DMEM 10% FCS, 3% agar. Cells were maintained by addition of 200 μl of DMEM 10% FCS weekly. After 3 weeks of growth a final count of colonies was performed. Cells not seeded into agar were incubated for a further 24h before efficiency of knock-down was assessed by RT-PCR and western blotting (Supplementary Figure 1).

Statistical analysis was performed as indicated with a significance level of 5%. 




RESULTS

Identification of candidate silenced genes involved in RCC
	DNA samples from 9 clear cell RCC tumours and 3 non-malignancy related kidneys were prepared by MeDIP and the resulting methylated and un-methylated fractions were hybridised to Nimblegen HG18 whole genome oligonucleotide arrays. Each gene is represented on the HG18 arrays by up to 14 probes grouped into “peaks”. A “peak score” of 2 equals a two-fold enrichment of DNA in the methylation immunoprecipitation fraction. A two-fold enrichment is the minimum level of methylation we have accepted to merit further investigation. 
	To prioritise the identification of gene promoters that were frequently methylated in RCC tumours we created a shortlist using the following criteria; there must be no methylation in any of the three non-malignancy related kidney samples and at least 45% (4/9) of RCC tumours must have a peak score ≥ 2. Applying these criteria gave a shortlist of 574 “peaks” which related to 443 individual genes and open reading frames (Supplementary Table 2 shows a full list of genes that had peak scores in 4/9 primary tumours). 
	To reduce the list of genes to those in which promoter methylation is likely to be biologically relevant we applied a further filter. We have previously analysed genome-wide expression changes in 11 RCC-derived cell lines following treatment with the demethylating agent 5-Aza-2’-deoxycytidine using Affymetrix U133 Plus-2 microarrays (Morris et al., 2010). We prioritised those genes from our MeDIP methylation array that also showed a significant re-expression (≥8 fold change, see Morris et al.,(2010)) in at least 2 cell lines, Seventy-eight genes met this criteria, including two, KRT19 and EDNRB, previously shown to be epigenetically silenced in RCC (Morris et al 2008, Pflug et al 2007) and two, RARRES1 and IRF7, have been shown to be infrequently methylated in RCC (Morris et al 2008). Eleven candidate genes were not analysed further as they had no CpG Island at the predicted promoter region (from www.genome.ucsc.edu (​http:​/​​/​www.genome.ucsc.edu​) and Genomatix promoter inspector (www.genomatix.de) (​http:​/​​/​www.genomatix.de)​)). X-chromosome and imprinted were also excluded (n=8). leaving 55 genes that have not previously been associated with epigenetic dysregulation in RCC as candidates for further analysis (See Figure 1 for a schematic of filtering criteria and Table 1 for a full list of candidate genes).

Validation of methylation in Candidate genes  
PCR primers were designed to amplify the predicted promoter region for all 55 candidate genes from bisulphite-modified DNA (see supplementary table 1 for primer details). Direct sequencing of promoter regions from 9 RCC cell lines and 6 normal kidneys obtained from non-RCC patients was performed to confirm the results from the MeDIP analysis. Genes were selected for further investigation if methylation was present in ≥40% of cell lines and absent in all 6 non-malignant kidney samples as determined by sequencing and CoBRA. Thirty-three promoter-GpG islands were frequently methylated in cell lines and not methylated in normal kidney tissue. The other CpG islands were either infrequently methylated in RCC cell lines (<40% n=11) or dense methylation ( 5% CpGs analysed) was present in normal kidney tissue (n=11) (Table 1).

Promoter Hypermethylation in Primary RCC tumours
To determine if the 33 candidate genes methylated in RCC cell lines were methylated in primary tumours we preformed CoBRA analysis in a further 6 normal kidney samples from patients with no history of RCC, up to 60 primary RCC and 18 normal kidney samples matched to 18 primary RCC. 
PKHD1L1, whilst frequently methylated in primary RCC (50%), was also found to be methylated in 2/6 additional normal kidney samples (2/12 normal kidney samples tested) and was excluded from further investigation. 
A two-stage protocol was employed to determine methylation frequency in primary RCC. Initially 20 primary RCC tumours were analysed, if the frequency of methylation was >15% a further 40 RCCs were tested. Of the 33 genes analysed 21 were not (CLDN1, DGKI, ALDH2, CACNB2, HTR1A, SLC29A4, NRARP, RHOD and PRRX2) or infrequently (≤15% of tumours; BIK, HMX1, ANK3, ALOX15, LYNX1, DUOX2, PROM1, CELSR3, P2RX5, LRRC2, SLC6A2 and TF) methylated. No further analysis was done on these genes. Twelve gene promoters were methylated in >15% of the first 20 tumours analysed but after testing of a further 40 RCC, two genes (IGFBP2 and EGR4) were methylated in <3% (1/40 tumours) of the additional samples and not further investigated. 
Nine gene promoters were frequently methylated (>15%), these were: ATP5G2 (36% of tumours methylated), PCDH8 (58% of tumours methylated), CORO6 (22% of tumours methylated), KLHL35 (39% of tumours methylated), QPCT (19% of tumours methylated), SCUBE3 (19% of tumours methylated), ZSCAN18 (32% of tumours methylated) CCDC8 (35% of tumours methylated) and FBN2 (34% of tumours methylated). These gene promoters were not methylated in any non-tumour kidney samples resected from regions adjacent to the tumours (n=18). The PTPLAD2 CpG island was methylated in 37% of primary tumours. However, methylation was also observed in 4/18 kidney samples restricted adjacent to the methylated tumours. Figure 2 shows representative CoBRA digest products.
	To analyse the methylation status of the nine genes that are frequently methylated in an RCC tumour-specific manner in more detail we carried out bisulphite sequencing in tumours which had been identified as methylatated by CoBRA (n=8 tumours per gene). The mean methylation index (MI) for the genes analysed by sequencing ranged from 25% to 59%% (SCUBE3; MI=25%, ZSCAN18; MI=43%, CORO6; MI=31%, FBN2 MI=31%, ATP5G2; MI=59%, QPCT; MI=34%, CCDC8= 52%, KLHL35; MI=39%, PCDH8; MI=44%). (Figure 3). Of the genes identified by this screen only one, DGKI, has been shown to be mutated in RCC, this was in 1 tumour out of 101 analysed (Dalgliesh et al 2010).

Expression analysis of identified genes
RT-PCR analysis of 22 pairs of tumour and corresponding non-tumour kidney cDNA confirmed that the genes identified by our screen were frequently silenced or down regulated. Transcripts were present in all tumour-matched normal kidney tissues and absent or significantly reduced (>5fold reduction compared to the corresponding normal sample) in many tumour samples: FBN2 (expression absent/reduced) in 55% of the 22 RCC), ATP5G2 (41%), KLHL35 (41%), PCDH8 (36%), CCDC8 (23%), QPCT (41%), SCUBE3 (45%), ZSCAN18 (23%) and CORO6 (41%). Tumours with absent/reduced expression were tested for gene methylation, for FBN2, ATP5G2, KLHL35, PCDH8 and CCDC8 most tumours tested demonstrated methylation (67%, 77%, 67%, 88% and 80% respectively). (Figure 4a). To further demonstrate that the presence of hypermethylated CpG islands was associated with the absence of each respective mRNA transcript we carried out RT-PCR on methylated cell lines. Treatment with the demethylating agent 5-Aza-2’-deoxycytidine (5 μM) for 5 days restored gene expression (Figure 4b). 

Functional analysis of the tumour suppressor activity of epigenetically inactivated genes
To investigate whether the promoter region methylation and transcriptional silencing might promote tumourigenesis, RNAi was used to knock down expression of the 9 methylated genes in HEK293 cells. Twenty-four hours after RNAi transfection cells were seeded into 3% agar, Colonies >200µm were counted 21 days later. Transcript knock down was determined by RT-PCR and western blotting where appropriate antibodies were available (Supplementary figure 1). Reduced expression of ATP5G2, PCDH8, or CORO6 did not result in a significant change in anchorage-independent growth. The number of resulting colonies >200µm following reduced expression of KLHL35 was 58% greater (SD=10%, p=0.009) than HEK 293 cells transfected with a control RNAi oligo. Reduced expression of QPCT resulted in 69% more colonies >200µm (SD=3%, p=0.003), SCUBE3 reduction produced 71% more colonies >200µm (SD=14%, p=0.01), Reduced expression of ZSCAN18, CCDC8 and FBN2 also significantly increased the number of anchorage independent colonies >200µm by 147% (SD=17%, p=0.0003), 154% (SD=5%, p=0.0003) and 205% (SD=17%, p=0.003) respectively (Figure 5) all experiments were done independently in triplicate.

Analysis of promoter methylation and patient survival/relapse
Kaplan-Meier analyses revealed no significant associations between the risk of cancer death/relapse and tumour methylation status for ATP5G2 (P = 0.5072), CCD8 (P = 0.1682), CORO6 (P = 0.4204), FBN2 (P = 0.4922), KLH35L (P = 0.2477), PCDH8 (P = 0.9912), QPCT (P = 0.2982) and ZSCAN (P = 0.5541). However methylation of SCUBE3 was associated with a significantly increased risk of death (P = 0.009) and cancer death or relapse (P = 0.0046) (Figure 6). 


DISCUSSION
Previously we and others had utilised functional epigenomic screens provide to identify epigenetically inactivated TSGs in RCC (Ibanez de Caceres et al 2006, Morris et al 2005, Morris et al 2008). In contrast to high throughput sequencing studies to detect genes mutated in RCC (Dalgliesh et al 2010), epigenetic studies have identified at least 18 genes that are inactivated in >20% of RCC (Morris et al., 2010 and references within) including SPINT2 (Morris et al 2005), BNC1, CST6, PDLIM4, COL14A1 and COL15A1 (Morris et al 2010). However, in order to facilitate the identification of further RCC TSGs we have utilised an approach that combined methylated-DNA Immunoprecipitation with comparative high-density whole genome microarray analysis and functional epigenomic expression data from RCC-derived cell lines treated with the demethylating agent 5-Aza-2’-deoxycytidine. Whilst this strategy also required a sequential prioritisation and analysis of genes to exclude those that were not frequently methylated in primary RCC, we were able to identify a further 6 genes that demonstrate promoter methylation in >30% of RCC and 3 genes that had promoter methylation in ≥19% of RCC. We note that several genes (e.g. SFRP1 (Dahl et al 2007, Morris et al 2010), DAPK1 (Christoph et al 2006, Morris et al 2003) and SPINT2 (Morris et al 2005)) that we and others have previously reported to be methylated in RCC were not identified by this strategy. This is likely to result from the promoter regions of these genes not being well covered by the HG18 methylation array and so suggests that further studies using higher density arrays (or more sensitive technologies) would lead to the identification of additional novel epigenetically regulated genes. Knock down of 6 of these genes was also shown to increase anchorage independent cell growth providing direct functional evidence of tumour suppressor activity. The HEK293 cell line was used as an experimental model for the tumourigenicity assays as all the target genes were expressed in this cell line (derived from Ad5-transformed embryonic kidney cells) and so the effect of each of the specific gene knockdowns could be evaluated in a consistent renal-derived cellular context. None of the 9 genes have not previously been reported to be methylated in RCC and, to the best of our knowledge, CCDC8, ATP5G2, KLHL35, CORO6, ZSCAN18 and SCUBE3 have not previously been reported to be methylated in neoplasia. FBN2 has recently been reported to be epigenetically silenced in colorectal, oesophageal and non-small cell lung cancers (Chen et al 2005, Tsunoda et al 2009, Yagi et al 2010). QPCT which encodes a glutaminyl cyclase (Fischer and Spiess 1987, Pohl et al 1991) is frequently methylated in malignant melanoma (Muthusamy et al 2006). Functional PCDH8 is frequently lost in breast cancer through both mutation and promoter methylation (Yu et al 2008) and also methylated in mantle cell lymphoma (Leshchenko et al 2010).
 FBN2 and the related gene FBN1 encode large modular extracellular matrix glycoproteins, that are key component of human microfibrils (Zhang et al 1994). The microfibrillopathies Marfan's syndrome and congenital contractural arachnodactyly (CCA) result from dominant mutations in FBN1 and FBN2 respectively (Robinson and Godfrey 2000). There is increasing evidence that these molecules regulate TGF-β signalling. The binding of TGF-β-bound large latency complex (LLC) to Fibrillins has two roles; it renders TGF-β inactive, facilitating fine control of TGF-β activity. It also concentrates TGF-β to specific locations thus regulating the biological response to TGF-β (Annes et al 2003). FBN1 mutations in Marfan's syndrome result in the excess activation of TGF-β  (Chaudhry et al 2007). However less is known about the role of Fibrillin-2. Loss of Fibrillin-2 in RCC may contribute to a malignant phenotype through contributing to the dysregulation of the complex network of signalling pathways regulated by TGF-β. Loss of large extracellular matrix proteins may also give angiogenic and metastatic advantages to RCC.
There is increasing evidence that protocadherins can function as tumour suppressors, Protocadherins 10 and 20 are epigenetically silenced in nasopharyngeal and lung cancers (Imoto et al 2006, Ying et al 2006) and recently it has been reported that PCDH8 is methylated in mantle cell lymphoma and breast cancer (Leshchenko et al 2010)(Yu et al 2008). Yu et al. found that re-expressing wt PCDH8 in a breast cancer cell line inhibited cell migration. Although, we did not find that silencing of PCDH8 increased the anchorage-independent growth potential of kidney cells, the role of protocadherins, and mechanism of action, in renal tumourigenesis is likely to merit further investigation.
QPCT encodes a glutaminyl cyclase that converts precursor glutaminyl peptides to their bioactive pyroglutaminyl peptide forms (Fischer and Spiess 1987, Pohl et al 1991) .Loss of expression of members of this family of protein have been observed in a number of tumour types including QPCT itself in melanoma (Muthusamy et al 2006) and phaeochromocytomas (Thouënnon et al 2007).  SCUBE (Signal peptide CUB EGF-like domain-containing protein) genes encode a small group of secreted plasma membrane-associated proteins characterised by a N-terminal signal peptide sequence, multiple EGF (Epidermal Growth Factor) domains, a large spacer region containing multiple N-linked glycosylation sites and a C-terminal CUB (Complement subcomponent C1r/C1s EGF-related sea Urchin protein, Bone morphogenetic protein1) domain (Grimmond et al 2000) Little is known about SCUBE3, however it is plausible to suggest that it may play an anti-tumourigenic role, in a similar manner to proteins such as gremlin (Morris et al 2010), in maintaining correct TGFbeta signalling. In addition, we note that methylation of SCUBE3 was associated with a significantly increased risk of cancer death/relapse. 
		The identification of frequent methylation of ATP5G2, which encodes a mitochondrial ATP synthase subunit C (Dyer and Walker 1993), in sporadic RCC is of interest as it is becoming increasingly apparent that mitochondrial dysregulation may play a significant role in the pathology of a number of tumour types, including RCC. Two common characteristics of tumours can both be related to errors in normal mitochondrial function, these are an increase in cellular energy production and the introduction of reactive oxygen species into the cellular environment which, in turn, can induce a hypoxic response (for a review see (Hüttemann et al 2008)). Other genes encoding metabolic processes such as the succinate dehydrogenases (SDH) and fumarate hydratase (FH) have previously been shown to be inactivated in familial RCC ((Morris et al 2003, Morris et al 2004, Ricketts et al 2008).
		Very little is known about the function of the CORO6 gene product (coronin-6), but the other members of the coronin family are actin-binding proteins that have been shown to function in cell motility, vesicle trafficking and cell division  (Roadcap et al 2008). Whether CORO6 has similar activity is unclear but such fundamental cell functions are often dysregulated in cancer. Similarly the function of KLHL35, CCDC8 and ZSCAN18 gene products are not well characterised but we note that RNAi induced downregulation of these transcripts resulted in some of the most significant growth advantages we observed in the anchorage-independent growth assay (to our knowledge there are no previous reports of a growth advantage to a non cancer cell line following the knockdown of these genes and also SCUBE3, QPCT and FBN2). These genes merit further investigation to determine their role in RCC. It will also be of interest to determine if these genes are dysregulated in a broader range of tumours.  
More than 200,000 new cases of kidney cancer are diagnosed in the world each year (Bray et al 2002) and although, if detected early partial nephrectomy is an effective treatment, many patients present with advanced disease. The response of metastatic RCC to conventional chemotherapy is poor but characterisation of the molecular pathology of RCC can provide a basis for developing novel therapeutic approaches. This is exemplified by the VHL TSG paradigm in which (a) inactivation of VHL is the most common event in sporadic clear cell RCC (Clifford et al 1998, Foster et al 1994, Herman et al 1994, Latif et al 1993), (b) VHL inactivation leads to stabilisation of HIF-1 and HIF-2 transcription factors and activation of hypoxic response genes that drive renal tumourigenesis (Maxwell et al 1999) and (c). inhibitors (e.g. tyrosine kinase inhibitors such as sorafenib and sunitinib) of HIF target pathways are active in the treatment of metastatic RCC (Chowdhury et al 2008). Hence, identification of frequently inactivated RCC TSGs can provide a basis for novel therapeutic interventions. Strategies to identify epigenetically inactivated TSGs therefore represent an important approach to elucidating the molecular pathogenesis of RCC and, furthermore, the detection of methylated RCC TSG DNA in urine or serum might be used as  biomarkers for the diagnosis, staging or risk stratification of RCC (Battagli et al 2003, Hoque et al 2006, Urakami et al 2006).Although confirmation is required, our findings suggest that SCUBE3 methylation status could be a prognostic marker in RCC. 
Previous RCC epigenetic studies (Breault et al 2005, Christoph et al 2006, Costa and Drabkin 2007, Ibanez de Caceres et al 2006, McRonald et al 2009, Morris et al 2005, Morris et al 2010, Yamada et al 2006) have identified candidate RCC TSGs that have functional roles in key pathways commonly dysregulated in cancer biology. Interestingly many of the genes identified in the present study that were shown to be frequently methylated or have in vitro growth suppressor activity, would not have been chosen as obvious candidate genes (none were represented in the 3544 genes sequenced in RCC by Dalgleish et al (2010). One advantage of unbiased genome-wide approaches, such as that employed in the present study is the potential to uncover novel genes and pathways that can be targeted for further investigation. 
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Figure Legends:

Table 1. Genes Shortlisted by combining MeDIP array and cell line expression array analysis. All shortlisted genes were analysed for promoter region methylation in RCC-derived cell lines and non-malignancy related kidney tissue. Those that were frequently methylated in RCC cell lines and not in normal tissue were then analysed in primary tumours. Those CpG Island regions that were methylated in primary tumours and not adjacent normal kidney were then analysed by bisulphite sequencing to provide details of methylation density within those regions as determined by mean methylation indices (Meth= Methylation, NM= Non-Malignant Kidney, Adj Norm= non-tumour kidney tissue resected from the same kidney as the relative tumour, MI= Methylation Index). Shading key; Green: Methylation present in RCC cell lines and primary tumours, No methylation in non-malignant kidney tissue. Yellow: Methylation in cell lines and 15% of primary tumours. No methylation in non-malignant kidney. Red: Methylation present in non-malignant kidney tissue. Blue: Methylation infrequent in RCC-derived cell lines (25%).
   
Figure 1 Schematic of method applied to shortlist candidate genes. Genes identified as methylated in primary RCC tumours and not in normal kidney DNA were compared to the differential expression of those genes in RCC-derived cell lines following culture in the de-methylating agent 5-Aza-2’-deoxycytidine. Those genes that were determined methylated by MeDIP array and re-expressed in at least 2 cell lines were considered for further analysis (see main text for further details).


Figure 2. Representative CoBRA digests. Sixty sporadic RCC tumours were analysed for promoter methylation. Nine genes were frequently methylated. ATP5G2 (36%), PCDH8 (58%), CORO6 (22%), KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%) CCDC8 (35%) and FBN2 (29%). The left hand panel is representative of tumours that were not methylated (un-meth T.), the other panels are representative of tumours that were methylated as determined by bisulphite PCR product digestion with BstU1 (ct= PCR product, BSTU1= PCR product digested with BSTU1).


Figure 3. bisulphite sequencing in tumours and non-malignant kidney resected adjacent to the tumour. Tumours that had been identified as methylatated by CoBRA (8 tumours per gene) were analysed by cloning and sequencing bisulphite-PCR products to determine the extent of methylation within the region analysed by CoBRA. The mean methylation index (MI) for the genes analysed by sequencing ranged from 25% to 59%% (SCUBE3; MI=25%, ZSCAN18; MI=43%, CORO6; MI=31%, FBN2 MI=31%, ATP5G2; MI=59%, QPCT; MI=34%, CCDC8= 52%, KLHL35; MI=39%, PCDH8; MI=44%). Methylation was absent in adjacent non-malignant kidney samples resected adjacent to the tumour (<5%MI in all cases). Each circle represents one CpG, shaded circles indicate presence of methyl-cytosine, clear circles indicate no methylation present. Two cell lines (which were sequenced directly), two methylated tumours (10 clones of each) and one adjacent kidney tissue (10 clones) are shown for each of the 9 genes. Methylation Index is defended as the total number of methylated CpG dinucleotides given as a percentage of all CpGs analysed. The mean MI is the average MI calculated for 10 clones per tumour. 

Figure 4. Candidate genes are frequently silenced in primary tumours. A: RT-PCR analysis of primary tumours (T) and non-malignant kidney resected adjacent to the tumour (N) showed that transcripts were present for all candidate genes in normal kidney found adjacent to tumours and was frequently silenced or significantly reduced in tumours (see main text for details). B: Re-expression of candidate genes in RCC cell lines following global de-methylation by addition of 5-Aza-2’-deoxycytidine to the growth media (5-Aza). Transcript absence correlated to methylation in the CpG island region analysed. De-methylation resulted in the re-expression of silenced transcripts (Single star indicates low level of expression prior to 5-Aza-2’-deoxycytidine treatment and increase expression after. Double star indicates complete silencing of transcript followed by re-expression following 5-Aza-2’-deoxycytidine treatment).


Figure 5. Knock-down of expression of FBN2, CCDC8, ZSCAN18, SCUBE3, QPCT or KLHL35 increases anchorage-independent growth potential. A. RNAi-induced reduced expression of FBN2, CCDC8, ZSCAN18, SCUBE3, QPCT or KLHL35 in HEK-293 cells resulted in the growth of significantly more colonies >200µm in diameter compared to cells transfected with a control RNAi oligo when seeded at the same density into soft agar (*=p<0.05, **=p<0.01, ***=p<0.001). Each gene knock-down experiment was  repeated three times.


Figure 6. Analysis of promoter methylation and patient survival/relapse. Kaplan-Meier analyses revealed Methylation of SCUBE3 was associated with a significantly increased risk of death (P = 0.009) and cancer death or relapse (P = 0.0046) (0= tumours with no SCUBE3 promoter methylation, 1= tumours with SCUBE3 promoter methylation).


Supplementary Table 1. Semi-nested PCR primers designed to amplify the CpG Island of candidate genes (F: Forward primer, IF: Internal Forward primer (2nd round), IR: Internal reverse primer (2nd round), R: Reverse primer).

Supplementary Table 2. List of genes (443) identified by MeDIP microarray analysis as methylated in a tumour specific manner (4/9 tumours had a Nimblegen “peak score” above 2).

Supplementary Figure 1. Validation of RNAi Knock-down in HEK-293 cells where  appropriate antibodies were available western blot analysis was done otherwise knockdown was determined by RT-PCR 48 hours post transfection. 



